FDA Brief

Warning letters Drugs

FDA warning letter to

Kabana Skin Care LLC

High riskIssued Jul 18, 2025Posted Jul 29, 2025Center for Drug Evaluation and Research (CDER)

Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

What happened

FDA inspected Kabana Skin Care's drug manufacturing facility in Louisville, Colorado, from February 19 to 20, 2025. FDA found the company did not test incoming ethanol and glycerin for identity, including methanol or diethylene glycol/ethylene glycol (DEG/EG), and did not perform chemical or microbiological testing on finished drug products before release. The company later agreed to recall all drugs in U.S. distribution and permanently cease manufacturing.

What FDA found

  1. Kabana did not test each incoming lot of ethanol and glycerin for identity, including methanol or DEG/EG contamination.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Kabana did not check that its component suppliers' test results were reliable at appropriate intervals.

    21 CFR 211.84(d)(2)
  3. Kabana did not perform chemical or microbiological release testing on finished drug batches before distribution.

    21 CFR 211.165(a)
  4. Kabana's quality control unit failed to ensure adequate oversight procedures for raw materials, production records, investigations, complaints, and recalls.

    21 CFR 211.22(a) and 211.22(d)
  5. Kabana lacked an adequate stability program to support labeled expiration dates.

    21 CFR 211.137 and 211.166
  6. Kabana lacked appropriate written production and process control procedures and adequate equipment cleaning and maintenance procedures.

    21 CFR 211.100(a), 211.67(a), 211.67(b)

What FDA wants

FDA tells Kabana to respond in writing within 15 working days with corrections and to provide methanol or DEG/EG test results from retained high-risk component lots and a risk assessment for products within expiry within 30 calendar days. The company must also notify FDA before resuming any drug manufacturing.

Who should pay attention

  • OTC drug brands that use contract manufacturers
  • companies buying glycerin or ethanol for drug products
  • retailers selling store-brand sunscreens or hand sanitizers

This is a summary. Read the original letter on fda.gov.

Kabana Skin Care LLC's FDA history

  1. Kabana Skin Care

    FDA warned Kabana Skin Care that its "Kabana Body Wash +UV" is an unapproved, misbranded sunscreen drug sold without required FDA clearance.

    Medium

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium